WALGREEN COMPANY for WALGREEN COMPANY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Financial Institutions/Investments/Securities FIN
S. 575- the "Debit Interchange Fee Study Act of 2011"- all provisions regarding studying the market and appropriate regulatory structure for electronic debit card transactions. HR. 1081- the "Consumers Payment System Protection Act" -all provisions regarding delaying the implementation of proposed or final rules issued under the authority of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the reasonable and proportional fees and rules for electronic debit transactions. H.R. 2010/ S. 1098-the "Family and Retirement Health Investment Act of 2011"- provisions related to payments from a HSA for prescription and over-the-counter medicine or drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN DEVRIES | — |
| DEBBIE GARZA | — |
| EDWARD KALETA | — |
| HEATHER HERNDON SMITH | — |
Health Issues HCR
H.R. 2267/S. 227- the "Home Health Care Planning Improvement Act"- provisions related to payments for home health care services. H.R. 5-the "Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011"-all provisions regarding capping damages at the greater of $250,000 or double the award of economic damages for certain health providers. H.R. 605/S. 312-the "Patient Freedom to Choose Act"-all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that restrict payments from health flexible spending arrangements for medications to prescription drugs and insulin.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD KALETA | — |
| HEATHER HERNDON SMITH | — |
Medicare/Medicaid MMM
S. 274- the "Medication Therapy Management Empowerment Act of 2011" -all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891-the "Medication Therapy Management (MTM) Benefits Act of 2011"-all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. H.R. 1936- the "Medicare Access to Diabetes Supplies Act of 2011" -provisions related to the exemption from Medicare competitive acquisition programs of blood glucose self-testing equipment and supplies furnished by small retail community pharmacies. H.R. 2195/S. 1203- the "Medicare Home Infusion Therapy Coverage Act"- provisions related to the Medicare coverage of home infusion therapy and home infusion drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBBIE GARZA | — |
| EDWARD KALETA | — |
| HEATHER HERNDON SMITH | — |
Pharmacy PHA
H.R.1540/S. 981- the "National Defense Authorization Act of FY 2012"- provisions related to the TRICARE pharmacy program. TRICARE-no specific legislation-regarding pharmacy services provided to TRICARE beneficiaries. H.R. 1971- the "Pharmacy Competition and Consumer Choice Act of 2011"- all provisions related to requirement of Pharmacy Benefit Managers annually reporting to Part D plan sponsors number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 3026- the "Safeguarding America's Pharmaceutical Act."-all provisions; Requires the Secretary of Health and Human Services (HHS) to issue regulations to establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors, and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. S. 1584- the "Drug Safety and Accountability Act"- all provisions; Authorizes the Secretary of Health and Human Services (HHS) to order an establishment to promptly revise its quality management plan in response to a significant threat to public health and requires each registered drug producer to report on each producer, manufacturer, distributor, and shipper involved in the production of a drug or the production or transport of the active ingredients of a drug. Requires the Secretary to develop and maintain information systems to track and assess every establishment that is involved in the manufacturing, preparation, propagation, compounding, or processing of a drug or active ingredient of a drug.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN DEVRIES | — |
| DEBBIE GARZA | — |
| EDWARD KALETA | — |
| HEATHER HERNDON SMITH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.